Skip to main content

Asuragen Raises $5M, Targeting $10M in Series C Round

NEW YORK (GenomeWeb News) – Molecular diagnostics shop Asuragen has raised $5 million toward a $10 million goal in its latest financing round.

In an e-mail to GenomeWeb Daily News, Asuragen Founder and CEO Matt Winkler confirmed the firm has closed the first $5 million of a $10 million Series C equity financing round, and added that the investment was made by an undisclosed "strategic venture investor."

"The proceeds of this round will accelerate the commercialization of our molecular diagnostics products and services," Winkler said, declining further comment.

Asuragen disclosed the financing in a document filed with the US Securities and Exchange Commission on Thursday.

Based in Austin, Texas, Asuragen was formed in 2006 and focuses on developing diagnostics for oncology and companion diagnostics using mRNA and microRNA technologies. According to its website, its product portfolio is comprised of multiplex oncology assays, RT-qPCR leukemia products, PCR assays for Fragile X testing, RNA stabilization technologies, and other things.

Asuragen had previously raised $18.5 million in a Series B round and $49 million in a Series A round.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.